The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
The European Association for the Study of Diabetes
59th Annual Congress 2-6 October 2023
Scientific publications at the 59th European Association for the Study of Diabetes Annual Meeting 2023.
Thank you for your interest! Please see below to download the posters/presentations at EASD 2023. Presentations, Videos and Posters will be available following the presentation at the congress.
Some of the links to view the Presentations or Posters will link to the official EASD 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.
Finerenone
Wednesday Oct 4 2023, 14:00 - 15:00
Finerenone increases the likelihood of improved KDIGO risk category in patients with type 2 diabetes and CKD: An analysis from FIDELITY
Short Oral Discussion Session: SO 52 Targeting muscle, kidney and liver Lead author: Silvio Inzucchi
Wednesday Oct 4 2023, 14:00 - 15:00
Impact of finerenone on chronic kidney disease progression in Chinese patients with type 2 diabetes: subgroup analysis of the FIGARO-DKD trial
Short Oral Discussion Session: SO 52 Targeting muscle, kidney and liver Lead author: Ping Li
Wednesday Oct 4 2023, 12:45-13:45
Clinical profile and kidney function of SGLT2i and GLP-1RA new users with CKD and T2D in Denmark: A nationwide population-based study part of the FOUNTAIN platform
Short Oral Discussion Session: SO 75 Clinical outcomes and biomarkers in diabetic kidney disease Lead author: Reimar W. Thomsen
